The lipid nanoparticle (LNP) coated delivery of siRNA molecules to the hepatocytes has been clinically proven to be highly effective for the treatment of hypercholesterolemia and transthyretin-induced amyloidosis. The gene discussed is TTR; the disease is Hypercholesterolemia.